Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.52 USD
+0.02 (0.57%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.53 +0.01 (0.28%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Repare Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -93.80 | -29.05 | -106.91 | -53.42 | -27.22 |
Depreciation/Amortization & Depletion | -5.51 | -0.26 | 1.58 | 0.90 | 0.61 |
Net Change from Assets/Liabilities | -55.18 | 4.41 | 7.00 | 43.70 | 6.59 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 27.34 | 25.22 | 12.53 | 2.74 | 1.59 |
Net Cash From Operating Activities | -127.16 | 0.32 | -85.80 | -6.08 | -18.43 |
Property & Equipment | -1.94 | -0.60 | -1.65 | -2.24 | -1.30 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 79.98 | -175.18 | -0.03 | -7.53 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 78.04 | -175.78 | -1.68 | -9.76 | -1.30 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.84 | 0.88 | 95.56 | 247.84 | 103.24 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.84 | 0.88 | 95.56 | 247.84 | 103.24 |
Effect of Exchange Rate Changes | 0.02 | -0.33 | -0.05 | -0.60 | 0.57 |
Net Change In Cash & Equivalents | -48.25 | -174.91 | 8.03 | 231.39 | 84.08 |
Cash at Beginning of Period | 159.52 | 334.43 | 326.40 | 95.01 | 10.93 |
Cash at End of Period | 111.27 | 159.52 | 334.43 | 326.40 | 95.01 |
Diluted Net EPS | -2.23 | -0.69 | -2.83 | -2.66 | NA |
Fiscal Year End for Repare Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -21.61 | 13.16 | -93.80 | -65.77 | -46.89 |
Depreciation/Amortization & Depletion | -1.92 | -0.74 | -5.51 | -4.36 | -2.98 |
Net Change from Assets/Liabilities | -9.15 | -7.50 | -55.18 | -49.28 | -29.74 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 14.10 | 7.02 | 27.34 | 20.41 | 13.47 |
Net Cash From Operating Activities | -18.58 | 11.93 | -127.16 | -99.00 | -66.13 |
Property & Equipment | 0.00 | 0.00 | -1.94 | -1.54 | -1.54 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -13.20 | -20.32 | 79.98 | 47.70 | 23.20 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -13.20 | -20.32 | 78.04 | 46.16 | 21.66 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.38 | 0.38 | 0.84 | 0.74 | 0.45 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.38 | 0.38 | 0.84 | 0.74 | 0.45 |
Effect of Exchange Rate Changes | -0.04 | -0.04 | 0.02 | -0.05 | 0.04 |
Net Change In Cash & Equivalents | -31.45 | -8.05 | -48.25 | -52.15 | -43.98 |
Cash at Beginning of Period | 111.27 | 111.27 | 159.52 | 159.52 | 159.52 |
Cash at End of Period | 79.82 | 103.22 | 111.27 | 107.37 | 115.54 |
Diluted Net EPS | -0.82 | 0.30 | -0.67 | -0.45 | -0.28 |